Rubius Therapeutics, Inc. Gains 48.58%
Thu, Sep 08, 2022 at 07:25 PM
Rubius Therapeutics, Inc. (RUBY:NASDAQ) rocketted at $1.29, representing a gain of 48.6%. On Thu, Sep 08, 2022, RUBY:NASDAQ touched a New 2-Week High of $1.29. From Thu, Aug 25, 2022, the stock recorded 55.56% Up Days and 40.00% Green Days
About Rubius Therapeutics, Inc. (RUBY:NASDAQ)
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
Top 10 Gainers:
- ShiftPixy, Inc. (PIXY:NASDAQ), 176.54%
- Amylyx Pharmaceuticals Inc. (AMLX:NASDAQ), 51.01%
- Rubius Therapeutics, Inc. (RUBY:NASDAQ), 48.58%
- Benitec Biopharma Inc. (BNTC:NASDAQ), 33.02%
- Marker Therapeutics, Inc. (MRKR:NASDAQ), 31.5%
- Palatin Technologies, Inc. (PTN:NYSEMKT), 26.2%
- LifeStance Health Group Inc. (LFST:NASDAQ), 25.76%
- Asana Inc. Class A (ASAN:NYSE), 24.79%
- Relay Therapeutics Inc. (RLAY:NASDAQ), 23.75%
- Revance Therapeutics, Inc. (RVNC:NASDAQ), 21.58%